Cargando…

VEGF signalling enhances lesion burden in KRIT1 deficient mice

The exact molecular mechanisms underlying CCM pathogenesis remain a complicated and controversial topic. Our previous work illustrated an important VEGF signalling loop in KRIT1 depleted endothelial cells. As VEGF is a major mediator of many vascular pathologies, we asked whether the increased VEGF...

Descripción completa

Detalles Bibliográficos
Autores principales: DiStefano, Peter V., Glading, Angela J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933401/
https://www.ncbi.nlm.nih.gov/pubmed/31746130
http://dx.doi.org/10.1111/jcmm.14773
_version_ 1783483206356434944
author DiStefano, Peter V.
Glading, Angela J.
author_facet DiStefano, Peter V.
Glading, Angela J.
author_sort DiStefano, Peter V.
collection PubMed
description The exact molecular mechanisms underlying CCM pathogenesis remain a complicated and controversial topic. Our previous work illustrated an important VEGF signalling loop in KRIT1 depleted endothelial cells. As VEGF is a major mediator of many vascular pathologies, we asked whether the increased VEGF signalling downstream of KRIT1 depletion was involved in CCM formation. Using an inducible KRIT1 endothelial‐specific knockout mouse that models CCM, we show that VEGFR2 activation plays a role in CCM pathogenesis in mice. Inhibition of VEGFR2 using a specific inhibitor, SU5416, significantly decreased the number of lesions formed and slightly lowered the average lesion size. Notably, VEGFR2 inhibition also decreased the appearance of lesion haemorrhage as denoted by the presence of free iron in adjacent tissues. The presence of free iron correlated with increased microvessel permeability in both skeletal muscle and brain, which was completely reversed by SU5416 treatment. Finally, we show that VEGFR2 activation is a common downstream consequence of KRIT1, CCM2 and CCM3 loss of function, though the mechanism by which VEGFR2 activation occurs likely varies. Thus, our study clearly shows that VEGFR2 activation downstream of KRIT1 depletion enhances the severity of CCM formation in mice, and suggests that targeting VEGF signalling may be a potential future therapy for CCM.
format Online
Article
Text
id pubmed-6933401
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-69334012020-01-01 VEGF signalling enhances lesion burden in KRIT1 deficient mice DiStefano, Peter V. Glading, Angela J. J Cell Mol Med Original Articles The exact molecular mechanisms underlying CCM pathogenesis remain a complicated and controversial topic. Our previous work illustrated an important VEGF signalling loop in KRIT1 depleted endothelial cells. As VEGF is a major mediator of many vascular pathologies, we asked whether the increased VEGF signalling downstream of KRIT1 depletion was involved in CCM formation. Using an inducible KRIT1 endothelial‐specific knockout mouse that models CCM, we show that VEGFR2 activation plays a role in CCM pathogenesis in mice. Inhibition of VEGFR2 using a specific inhibitor, SU5416, significantly decreased the number of lesions formed and slightly lowered the average lesion size. Notably, VEGFR2 inhibition also decreased the appearance of lesion haemorrhage as denoted by the presence of free iron in adjacent tissues. The presence of free iron correlated with increased microvessel permeability in both skeletal muscle and brain, which was completely reversed by SU5416 treatment. Finally, we show that VEGFR2 activation is a common downstream consequence of KRIT1, CCM2 and CCM3 loss of function, though the mechanism by which VEGFR2 activation occurs likely varies. Thus, our study clearly shows that VEGFR2 activation downstream of KRIT1 depletion enhances the severity of CCM formation in mice, and suggests that targeting VEGF signalling may be a potential future therapy for CCM. John Wiley and Sons Inc. 2019-11-20 2020-01 /pmc/articles/PMC6933401/ /pubmed/31746130 http://dx.doi.org/10.1111/jcmm.14773 Text en © 2019 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for cellular and Molecular Medicine and John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
DiStefano, Peter V.
Glading, Angela J.
VEGF signalling enhances lesion burden in KRIT1 deficient mice
title VEGF signalling enhances lesion burden in KRIT1 deficient mice
title_full VEGF signalling enhances lesion burden in KRIT1 deficient mice
title_fullStr VEGF signalling enhances lesion burden in KRIT1 deficient mice
title_full_unstemmed VEGF signalling enhances lesion burden in KRIT1 deficient mice
title_short VEGF signalling enhances lesion burden in KRIT1 deficient mice
title_sort vegf signalling enhances lesion burden in krit1 deficient mice
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933401/
https://www.ncbi.nlm.nih.gov/pubmed/31746130
http://dx.doi.org/10.1111/jcmm.14773
work_keys_str_mv AT distefanopeterv vegfsignallingenhanceslesionburdeninkrit1deficientmice
AT gladingangelaj vegfsignallingenhanceslesionburdeninkrit1deficientmice